2026 NEXTGEN HEAD & NECK CANCER MEETING

The pace of discovery in head and neck oncology has significantly accelerated in the past decade with new indications for multiple therapies, advances in surgical management, and novel tools for surveillance. To this end, 2026 NextGen H&N will host speakers from around the country, including those very investigators who are leading these changes, to present current data to support new treatments. We will focus on novel, innovative approaches that have translated into clinical practice. In 2026, the meeting will present emerging developments in perioperative immunotherapy for mucosal head and neck cancer, circulating tumor DNA, and de-intensification strategies for HPV-associated oropharyngeal cancer. The educational format will include clinical trial highlight segments, debate-focused panel discussions, and a novel clinical trial concept session. Attendees can expect a single day of high impact presentations from dynamic speakers, discussion on the direction of our multidisciplinary field, and promotion of collaboration to enhance patient care.

Session Educational Objectives:

  1. Optimize decision making for incorporating perioperative immunotherapy into clinical practice.
  2. Integrate clinical applications of ctDNA in head and neck cancer, including testing intervals.
  3. Recognize the strengths and limitations of current de-intensification strategies for HPV-positive head and neck cancer and consider how these principles may be integrated into practice.

Target Audience: Head and neck medical, radiation, and surgical oncologists; clinical and translational researchers; trainees including residents and fellows; pharmacists; advanced practice providers involved in head and neck oncology; as well as industry medical liaisons and collaborators.

The Course Co-Directors are Michael Topf, MD, MSCI; Eben Rosenthal, MD; and Glenn Hanna, MD.

Course Faculty to be updated soon.

  • SATURDAY, NOVEMBER 7, 2026

    Session I: Perioperative Immunotherapy Approaches in Mucosal Head and Neck Cancer

    8:00 – 8:20 AMEvolving Pathologic Response Assessment: AI and the FutureGerman Corredor Prada, MD
    8:20 – 8:40 AMAdaptive Surgery Following Neoadjuvant TherapyAdam Luginbuhl, MD
    8:40 – 9:00 AMEmerging Biomarkers and Correlatives in Perioperative HNSCC Treated with ImmunotherapyLuana Sousa, MD
    9:00 – 9:10 AMTrial Highlight: SHRINK‑RAY – Neoadjuvant Pembrolizumab + SBRT with Risk‑Adapted Adjuvant Therapyavid Schwartz, MD
    9:10 – 9:20 AMTrial Highlight: Phase II Cetuximab / Cemiplimab Study 
    9:20 – 10:00 AMPanel Debate: Neoadjuvant vs. Adjuvant ImmunotherapyChristine Chung, MD
    10:00-10:30 AMCoffee Break & Networking 

    Session II: Circulating Tumor DNA in Mucosal Head and Neck Cancer

    10:30 – 10:50 AMHPV‑ DNA Detection in Drain FluidKevin Contrera, MD
    10:50 – 11:10 AMHPV‑Positive ctDNA ToolsCate Haring, MD
    11:10 – 11:30 AMHPV‑Agnostic ctDNA ToolsGlenn J. Hanna, MD
    11:30 AM – 12:00 PMTopic Debate: Adopting ctDNA into Clinical Practice Now 
    12:00-1:00 PMLunch 

    Session III: Clinical Trials Pitch & Planning Forum

    1:00 – 1:20 PMClinical Trial Concept (1)10‑minute schema presentation
    / 10‑minute group feedback
    1:20 – 1:40 PMClinical Trial Concept (2)10‑minute schema presentation
    / 10‑minute group feedback
    1:40 – 2:00 PMClinical Trial Concept (3)10‑minute schema presentation
    / 10‑minute group feedback

    Session IV: The Current Landscape of HPV‑Associated Oropharyngeal Cancer De‑Intensification

    2:00 – 2:20 PMElective Nodal IrradiationQuynh Le, MD
    2:20 – 2:40 PMNeoadjuvant NIRTBryan Bell, MD
    2:40 – 3:00 PMNew and Emerging Targeted Therapies for HPV De‑IntensificationNadeem Riaz, MD
    3:00 – 3:10 PMTrial Highlight: ctDNA‑Based De‑Intensification Following TORSJames Bates, MD
    3:10 – 3:20 PMTrial Highlight: FDG‑PET‑Based Selective De‑Escalation of Chemoradiation in HPV‑Related OPSCCMichelle Mierzwa, MD
    3:20 – 3:30 PMTrial Highlight: REACTJohn Schoenfeld, MD
    3:30 – 4:00 PMTopic Debate: Where Does HPV‑Associated De‑Intensification Go 
    4:00-6:00 PMAdjournment & Networking Cocktail Hour